EGFR and non-small cell lung carcinoma: Many trials suggest that TKIs treatment in patients with EGFR-mutated NSCLC has a significant survival benefit, and other combined treatment of chemotherapy and TKIs also significantly improve progression-free survival (PFS) in advanced NSCLC [5].